Marieke van Son

21 GENERAL INTRODUCTION AND THESIS OUTLINE 46. Pederson AW, Fricano J, Correa D, Peliz- zari CA, Liauw SL. Late toxicity after in- tensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointesti- nal toxicity. Int J Radiat Oncol Biol Phys. 2012;82(1):235-41. 47. Ohri N, Dicker AP, Showalter TN. Late tox- icity rates following definitive radiother- apy for prostate cancer. The Canadian journal of urology. 2012;19(4):6373-80. 48. Lesperance RN, Kjorstadt RJ, Halligan JB, Steele SR. Colorectal complica- tions of external beam radiation versus brachytherapy for prostate cancer. Am J Surg. 2008;195(5):616-20; discussion 20. 49. Mahmood J, Shamah AA, Creed TM, Pavlovic R, Matsui H, Kimura M, et al. Radiation-induced erectile dysfunction: Recent advances and future directions. Adv Radiat Oncol. 2016;1(3):161-9. 50. Incrocci L. Radiotherapy for prostate cancer and sexual health. Translational andrology and urology. 2015;4(2):124-30. 51. Rees J, Patel B, MacDonagh R, Persad R. Cryosurgery for prostate cancer. BJU international. 2004;93(6):710-4. 52. Madersbacher S, Marberger M. High-en- ergy shockwaves and extracorporeal high-intensity focused ultrasound. Jour- nal of endourology. 2003;17(8):667-72. 53. Ramsay CR, Adewuyi TE, Gray J, Hislop J, Shirley MD, Jayakody S, et al. Ablative therapy for people with localised pros- tate cancer: a systematic review and economic evaluation. Health technology assessment. 2015;19(49):1-490. 54. Chin JL, Al-Zahrani AA, Autran-Gomez AM, Williams AK, Bauman G. Extended followup oncologic outcome of random- ized trial between cryoablation and ex- ternal beam therapy for locally advanced prostate cancer (T2c-T3b). The Journal of urology. 2012;188(4):1170-5. 55. Donnelly BJ, Saliken JC, Brasher PM, Ernst SD, Rewcastle JC, Lau H, et al. A randomized trial of external beam radio- therapy versus cryoablation in patients with localized prostate cancer. Cancer. 2010;116(2):323-30. 56. Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiothera- py for Prostate Cancer. N Engl J Med. 2016;375(15):1425-37. 57. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Outcomes of localized prostate cancer follow- ing conservative management. Jama. 2009;302(11):1202-9. 58. Chodak GW, Thisted RA, Gerber GS, Jo- hansson JE, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330(4):242-8. 59. Chen RC, Rumble RB, Loblaw DA, Finelli A, Ehdaie B, Cooperberg MR, et al. Active Surveillance for the Management of Lo- calized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(18):2182-90. 60. Lam TBL, MacLennan S, Willemse PM, Mason MD, Plass K, Shepherd R, et al. EAU-EANM-ESTRO-ESUR-SIOG Pros- tate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collabora- tive Study (DETECTIVE Study). Eur Urol. 2019;76(6):790-813. 61. van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH. Prospective validation of active sur- veillance in prostate cancer: the PRIAS study. Eur Urol. 2007;52(6):1560-3. 1